XML 72 R58.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
May 10, 2021
May 17, 2022
Feb. 25, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 20, 2018
May 25, 2022
Jan. 01, 2022
Outstanding principal balance       $ 2,158,417 $ 5,503,507      
Debt instrument conversion price             $ 15.54  
Shares issued       10,605,412 701,780      
Prepaid expenses       $ 7,599,545        
Accrued interest       $ 275,547 $ 1,019,889      
Interest rate       10.00%        
Repaid amount       $ 1,806,678 3,045,000      
Revenue       50,347,652 56,239,667      
Grigorios Siokas [Member]                
Borrowing         2,933,165 $ 1,718,400   $ 702,591
Outstanding principal balance       452,720        
Accrued interest       206,355        
Interest rate           4.70%    
Maturity date           Mar. 18, 2019    
Litigation settlement $ 600,000              
Plantiff attorney fees 120,000              
Litigation cost $ 4,137              
Grigorios Siokas [Member] | February Note [Member] | Senior Promissory Note [Member]                
Interest rate     18.00%          
Maturity date     Apr. 30, 2020          
Grigorios Siokas Three [Member]                
Borrowing       2,040,635        
Outstanding principal balance       1,293,472        
Additional proceeds from debt       275,306        
Repayment of loans       133,552        
Foreign curreny translation       $ 64,729 20,623      
Debt instrument conversion price       $ 150.00        
Convertible share description       Mr. Siokas whereby the Company exchanged an aggregate total of $6,000,000 of debt into 40,000 shares of Common Stock at above market prices.        
Debt instrument converted amount       $ 2,250,000        
Shares issued       15,000        
Dimitrios Goulielmos [Member]                
Outstanding principal balance       $ 10,912 11,544      
DOC Pharma S.A. [Member]                
Foreign curreny translation       $ 19,568 37,411      
Interest rate       5.50%        
Payments to purchase products       $ 1,755,103 3,084,805      
Accounts payable balance       201,991 565,756      
Accounts receivable balance       2,070,570 2,901,300      
Prepaid balance       3,320,345 3,263,241     $ 4,279,200
Revenue       $ 1,058,780 978,321      
Agreement term       5 years        
Pieces per product       1,000 pieces        
Loan current portion       $ 427,920        
Loan non-current portion       3,851,280        
Inventroy purchase       $ 1,742,282 2,010,517      
Description of research and development   Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($289,860) from Doc Pharma which was the 18.33% of the total cost.   SkyPharm bought another 14 licenses at a value of €293,200 ($313,665) from Doc Pharma which was the 20.57% of the total cost. SkyPharm has bought in total as of December 31, 2022, 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost. The agreement will be terminated on December 31, 2025.        
Panagiotis Kozaris [Member]                
Shares owned       143,056        
Prepaid expenses   $ 143,056   $ 0        
Prepaid balance       376,901        
Maria Kozari [Member]                
Accounts receivable balance       760,025 366,270      
Prepaid balance       48,230        
Net sales       463,467 $ 358,524      
Cumulative bad debt allowance       $ 59,957